IMMUNISATION PROGRAMMES depend on permanent sufficient and reliable supplies of high-quality vaccines. In recent years, many countries on a global base have reported vaccine deficits, and UNICEF has identified insufficient supply of a wide range of vaccines for routine and emergency immunisation, including diphtheria, tetanus and pertussis (DTP) vaccines and inactivated polio vaccines. Such kind of vaccines are the subject of our work. In general vaccine manufacturing is complex, lengthy and highly regulated: production can often take more than a year and depends on several conditions. Without reliable demand from purchasers, manufacturers face challenges in keeping their production lines available: multiple stakeholders and market giants can help to minimise this risk and incentivise ongoing production by companies. It is critical that companies and other stakeholders can effectively share information and promptly respond to issues around demand forecasting, manufacturing interruptions and regulatory changes. The Access to Vaccines Index examines companies’ processes, strategies and commitments for preventing and responding to deficits. By aligning vaccine supplying plans with global demand, companies are helping to avoid both under- and over-supply that could harm the sustainability of vaccine markets.

BULVAX make the strongest commitment to maintaining supply of the distributed and marketed vaccines for as long as they are required: it does not discontinue any vaccines used to prevent serious disease for which there are no alternatives on the market. BULVAX also engages with key purchasers, such as UNICEF, PAHO, national authorities, ngos and wholesalers, before exiting major markets and, where possible, in case of upcoming supply disruptions. It prioritises public health needs when distribute the marketed products. Our partners approaches is particularly important because they are some of the few producers of vaccines available for several diseases, including pertussis; diphtheria; tetanus; tuberculosis; Crimean-Congo hemorrhagic fever; etc.. BULVAX has clear processes for proactively engaging with purchasers to align supply and demand. The company contributes to global vaccine stockpiles has worked with partners to improve planning and stock management processes related to these stockpiles.

THE MAIN GROUP of the marketed and distributed medicinal products by BULVAX are vaccines.
They protect against the following diseases: • pertussis; • diphtheria; • tetanus; • tuberculosis; • Crimean-Congo hemorrhagic fever.
The combined vaccines are produced for European and Global markets.
The vaccines marketed and distributed by us have well established usage, and proved safety and efficacy on a global scale.
PART OF THE PRODUCTION, distributed and marketed by BULVAX also covers polybacterial immunostimulators.
They are composed of lyophilized lysates and killed bacterial bodies of the microorganisms, selected so that these are the most important causative agents of nonspecific inflammatory diseases of the respiratory and urogenital system. Suitable for adults and children. The products contain the full antigenic and immunostimulatory activity of these bacteria. They cause synthesis of specific/homologous protective IgG, IgA and IgM antibodies, thus acting as specific „bacterial vaccines“.
Please, contact us to provide the complete Product list of BULVAX.